AT268595T

Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

37 members in 12 offices

This recordMember, by publication datePriority claim2 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
11261798United States of AmericaP
11261798United States of AmericaP
9902095International Bureau of the World Intellectual Property Organization (WIPO)W
9902095International Bureau of the World Intellectual Property Organization (WIPO)W
112617P
9902095
US19980112617P
WO1999IB02095

Members37

Family members, oldest first
DocumentOfficeKind
CA2355854A1CanadaA1
WO0035426A2World Intellectual Property Organization (WIPO)A2
AU2122700AAustraliaA
WO0035426A3World Intellectual Property Organization (WIPO)A3
EP1143937A2European Patent Office (EPO)A2
US6419960B1United States of AmericaB1
JP2002532410AJapanA
US2003054033A1United States of AmericaA1
EP1143937B1European Patent Office (EPO)B1
AT268595TThis recordAustriaT
ATE268595T1AustriaT1
DE69917937D1GermanyD1
DK1143937T3DenmarkT3
PT1143937EPortugalE
SI1143937T1SloveniaT1
ES2224740T3SpainT3
DE69917937T2GermanyT2
US7247318B2United States of AmericaB2
US2007264325A1United States of AmericaA1
CA2355854CCanadaC
US7438930B2United States of AmericaB2
JP4172917B2JapanB2
US2009123554A1United States of AmericaA1
US8580310B2United States of AmericaB2
US2014099361A1United States of AmericaA1
US9066869B2United States of AmericaB2
US2015313850A1United States of AmericaA1
US2017071926A1United States of AmericaA1
US2017079921A1United States of AmericaA1
US2017135999A1United States of AmericaA1
US9801823B2United States of AmericaB2
US2018008544A1United States of AmericaA1
US2018042854A1United States of AmericaA1
US9949931B2United States of AmericaB2
US10022330B2United States of AmericaB2
US10039719B2United States of AmericaB2
US10463624B2United States of AmericaB2